Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
555 participants
INTERVENTIONAL
2004-07-31
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GALLANT 4 Tesaglitazar vs. Glibenclamide
NCT00255541
GALLANT 22 Tesaglitazar vs. Placebo
NCT00252837
GALLANT 8 Tesaglitazar Add-on to Metformin
NCT00251953
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
NCT00242372
GALLANT 5 Tesaglitazar Versus Metformin
NCT00214591
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tesaglitazar 0.5 or 1 mg
Glibenclamide 2.5, 5, 10 or 15 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
* Diagnosed with type 2 diabetes
* Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
Exclusion Criteria
* New York Heart Association heart failure Class III or IV
* Treatment with chronic insulin
* History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
* History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
* Creatinine levels above twice the normal range
* Creatine kinase above 3 times the upper limit of normal
* Received any investigational product in other clinical studies within 12 weeks
* Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Galida Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Adelaide, , Australia
Research Site
Brisbane, , Australia
Research Site
Cairns, , Australia
Research Site
Geelong, , Australia
Research Site
Melbourne, , Australia
Research Site
Perth, , Australia
Research Site
Sydney, , Australia
Research Site
Tasmania, , Australia
Research Site
Angers, , France
Research Site
Hyères, , France
Research Site
La Garde, , France
Research Site
La Seyne-sur-Mer, , France
Research Site
Laval, , France
Research Site
Le Brusc, , France
Research Site
Le Lavandou, , France
Research Site
Montrevault, , France
Research Site
Paris, , France
Research Site
Saint-Cyr, , France
Research Site
Six-Fours-les-Plages, , France
Research Site
Tiercé, , France
Research Site
Toulon, , France
Research Site
Ashkelon, , Israel
Research Site
Haifa, , Israel
Research Site
Holon, , Israel
Research Site
Jerusalem, , Israel
Research Site
Rishon LeZiyyon, , Israel
Research Site
Safed, , Israel
Research Site
Tel Aviv, , Israel
Research Site
Tel Litwinsky, , Israel
Research Site
Bergen, , Norway
Research Site
Elverum, , Norway
Research Site
Enebakk, , Norway
Research Site
Fredrikstad, , Norway
Research Site
Gamle Fredrikstad, , Norway
Research Site
Hamar, , Norway
Research Site
Haugesund, , Norway
Research Site
Hurdal, , Norway
Research Site
Inderøy, , Norway
Research Site
Lena, , Norway
Research Site
Levanger, , Norway
Research Site
Oslo, , Norway
Research Site
Rud, , Norway
Research Site
Sedsmokorset, , Norway
Research Site
Soerumsand, , Norway
Research Site
Stavanger, , Norway
Research Site
Manila, , Philippines
Research Site
Marikina City, , Philippines
Research Site
Pasig, , Philippines
Research Site
Cape Town, , South Africa
Research Site
Chatsworth, , South Africa
Research Site
Gauteng, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Seoul, , South Korea
Research Site
Suwon, , South Korea
Research Site
Alzira (Valencia), , Spain
Research Site
Barcelona, , Spain
Research Site
Guissona (Lleida), , Spain
Research Site
Madrid, , Spain
Research Site
San Sebastian de Los Reyes ( Madrid), , Spain
Research Site
San Vicente de Raspeig (Alicante), , Spain
Research Site
Valencia, , Spain
Research Site
Dublin, Ireland, United Kingdom
Research Site
Aberdeen, , United Kingdom
Research Site
Barnsley, , United Kingdom
Research Site
Bath, , United Kingdom
Research Site
Belfast, , United Kingdom
Research Site
Birmingham, , United Kingdom
Research Site
Cardiff, , United Kingdom
Research Site
Coventry, , United Kingdom
Research Site
Dundee, , United Kingdom
Research Site
East Sussex, , United Kingdom
Research Site
Edinburgh, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
Liverpool, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Shrewsbury, , United Kingdom
Research Site
Surrey, , United Kingdom
Research Site
West Midlands, , United Kingdom
Research Site
Wiltshire, , United Kingdom
Research Site
Wrexham, , United Kingdom
Research Site
Hanoi, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT No 2004-001144-71
Identifier Type: -
Identifier Source: secondary_id
D6160C00032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.